A case report of blastic plasmacytoid dendritic cell neoplasm in a hispanic child

Katy Ordoñez Tanchiva, Pamela Contreras Chavez, Silvana Lucero Loli Guevara, Carlos Rodrigo Quispe Vicuña, Neharika Bhardwaj, Frederick Lansigan, Erik Deconinck

1. Introduction

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematological neoplasm, which has its own category in the group of leukemias [1]. It has been reported close to 0.04 per 100,000 incidence population worldwide [2], while probably heterogeneously distributed, Latin America’s incidence is still unknown.

It usually presents in elderly people, and clinical manifestations include nodular blue-violet skin lesions, bone marrow infiltration and, less frequently, extramedullary involvement [3]. In pediatric patients, clinical characteristics do not differ significantly; however, better survival has been found in children [3, 4]. Despite some associations with other hematological neoplasms that have been described, its etiology is still not clearly known [5]. Diagnosis is based on immunohistochemistry; it requires the positivity of CD4 and CD56 markers, and at least two other dendritic cell markers [6].

Current literature, based on case reports in children supports the use of acute leukemia treatment regimens as the most beneficial option [7]. While, recently, a larger cohort in adults has reported the best outcomes for AL-like regimen followed by allogenic hematopoietic stem cell transplantation [8]. Although there is no standardized treatment for BPDCN, one study reported that adults treated with AML-like, ALL-like and high-dose methotrexate with asparaginase (Aspa-MTX) chemotherapies showed increased survival and remission compared to other treatments such as CHOP-like (classical regimen used in the treatment of non-Hodgkin lymphomas and combining cyclophosphamide, doxorubicin, vincristine, and prednisone) and not otherwise specified (NOS) regimens (all other drugs alone or in combination) [9]. In pediatric patients, despite lacking standardized treatment, good results have been obtained with new therapies targeting CD123 like SL-401 (tagraxofusp) [10] which are currently approved and used as more specific treatment in adults and only few reports in children, this approach is not yet standardized, but good results have been seen with the pediatric ALL protocol [11] in children and young adults.

The objective of this current pediatric case is to document the diagnosis of this rare disease in a child without any clinical suspicion of leukemia and report complete remission after a protocol for high-risk acute lymphoblastic leukemia.
We report a case of an 11 year old male from Peru who was referred from a local hospital in the highlands to the National Institute of Neoplastic Diseases (INEN) in Lima, with the diagnosis of ‘Round Cell Neoplasia’.

This child presented with a 2-year clinical history of a growing mass in the anterior inner middle third of the right leg, of approximately 5 cm by time of medical consultation, blue-violet coloring, increased consistency, poorly defined edges and mild pain on palpation, without functional limitation. No other epidemiological, personal, family or medical history of importance was reported.

The physical examination showed a 7 cm long surgical scar with ulcerated area and granulation tissue without signs of infection seen from the past biopsy (Fig. 1). Also, he presented right inguinal multiple adenopathies of 3 × 3 cm, mobile, painless and without phlogosis. The rest of the physical examination was unremarkable.

Final diagnosis was made through immunohistochemistry and by excluding more frequent neoplasms. Thus, the positivity for CD4, but negativity of CD3, served to rule out a T cell neoplasm. In the same way, excluding more frequent neoplasms. Thus, the positivity for CD4, but negativity for CD3, removed the possibility of TCL1) which allowed confirmation of the diagnosis [13]. Other dendritic cell markers not tested in this case are CD68, CD123 and BDCA-2/CD303 [14]. This patient also showed positivity for terminal deoxynucleotidyl transferase (TdT), which is associated to a better prognosis [8].

Laboratory values of hemoglobin, leukocytes, segmented, platelets, and erythrocyte sedimentation rate values were normal. Morphology, flow cytometry and bone marrow biopsy were negative to infiltration of neoplastic cells. After the medical team discussion, an institutional HR-ALL protocol was indicated (Table 1). The high-risk classification was indicated because of the patient’s age and the biological characteristics of this rare disease. Patient had complete response after protocol given with remission currently.

During treatment, two emergent admissions were required due to febrile neutropenia, and both resolved without complications. By the date of submit of this report, the patient was in good general condition. He completed maintenance chemotherapy phase in May 2020, and stays in follow up appointments without treatment related complications.

### Table 1

| Phase and procedures | Dosis | Days |
|----------------------|-------|------|
| Phase IA | | |
| Dexamethasone(IV/VO) | 6 mg/m²/ day | 1–29 |
| Prednisone (VO) | 60 mg/m²/ day | 1–29 |
| Daunorubicin (IV) | 1.5 mg/m² | 1, 8, 15, 22 |
| L-Asparaginase (IV/IM) | 10,000 UI/m² | 5, 6, 10, 13, 17, 20 |
| Lumbar puncture with QTIT application | – | 7, 14 |
| Bone marrow study | – | 7, 14–14 |
| BM study with EMR and LP with QTIT application | – | 29 |
| IB PHASE increased | | |
| Cyclophosphamide (IV) | 1000 mg/m² | 1, 29 |
| Cytarabine (IV) | 75 mg/m² | 1–4, 8–11, 29–32, 36–39 |
| 6-Mercaptopurine (VO) | 60 mg/m²/ day | 1–4 y 36–49 |
| Vincristine (IV) | 1.5 mg/m² | 15, 22, 43, 50 |
| Asparaginase (IV/IM) | 10,000 UI/m² | 17, 20, 24, 27, 45, 48, 52, 55 |
| Lumbar puncture with QTIT application | – | 14, 28, 42 |
| MO study with EMR and PL with QTIT application | – | At the end of this phase |
| Consolidation | | |
| Methotrexate (IV) | 2 g/m³ | 1, 15, 29, 43 |
| Leucovorin(VO) | 15 mg/m³ | 42, 48 y 54* |
| Vincristine (IV) | 1.5 mg/m³ | 1, 15, 29, 43 |
| Mercaptopurine (VO) | 25 mg/m²/ dosis | 1–56 |
| Lumbar puncture with QTIT application | – | 28 |
| MO/PL with QTIT application | – | At the end of this phase |
| Increased induction (Phase II or increased re-induction) | | |
| Vincristine (IV) | 1.5 mg/m³ | 1, 8, 15, 22 |
| Doxorubicin (IV) | 25 mg/m³ | 1, 8, 15, 22 |
| Dexamethasone (VO) | 6 mg/m³ | 1–21 |
| L-Asparaginase (IM) | 10,000 UI/m² | 3, 6, 10, 13 |
| Lumbar puncture with QTIT application | – | 14, 35 |
| Cyclophosphamide (IV) | 1000 mg/m² | 36 |
| Cytarabine (IV) | 75 mg/m³ | 36, 37, 38, 39, 43, 44, 45, 46 |
| Thioguanine (VO) | 60 mg/m³/ día | 36–49 |
| Vincristine (IV) | 1.5 mg/m³ | 50, 57 |
| Asparaginase (IM) | 10,000 UI/m² | 52, 55, 59, 62 |
| Lumbar puncture with QTIT application | – | 42 |
| BM/PL with QTIT application | – | At the end of this phase |
| Maintenance | | |
| Vincristine (IV) | 1.5 mg/m³ | 1 |
| Prednisone | 40 mg/m³ | During 5 days |
| Mercaptopurine (VO) | 50 mg/m² | Daily |
| Methotrexate (VO) | 15 mg/m³ | Weekly |
| Lumbar puncture with QTIT application | – | Monthly (6 months) |

VO: oral; IV: intravenous; IM: intramuscular; QTIT: intrathecal chemotherapy; BM: Bone marrow; LP: Lumbar puncture; EMR: minimal residual disease; *: Hours after initiation of methotrexate.

2017 review [3]. However, it did not include data in Spanish or from Latin America, and its clinical progress has not been considered before. Also, this patient experienced a delay in diagnosis due to lack of resources at a hospital outside the country’s capital (as seen in many low-middle income countries), which points out the indolent course of the neoplasm in this case. A systematic literature review showed the mean survival of patients under 40 years was 38 months [3]. Similarly, another study showed the overall survival in children at 3 years was 57.4 ± 10.2 months [15].
Significant lymphadenopathies in the right external iliac chain and right inguinal region were found on multi-slice spiral computed tomography scans. These typical secondary lesions were considered as inguinal metastasis.

The child had a prior biopsy in the highlands, but it was insufficient tissue and INEN’s oncology pediatric team performed a new biopsy. Hematoxylin and eosin staining and immunohistochemical markers were studied. It showed CD4+ and CD56+; staining for more specific markers resulted in a local TdT+, CD45+, TCL1+ and CD34-. In addition, the KI-67 score was 60% (Fig. 2).

Bone marrow compromise and leukemic expression can appear even without skin lesions in 60–90% of cases [3,4]. In this child, even after two years of evolution before the diagnosis, there was no bone marrow infiltration. Extramedullary manifestations include involvement of the liver, lymph nodes (40%–50%), sinuses, orbits and central nervous system, rarely splenomegaly (20%) and fulminant leukemia (5–25%) [3,4], in this case only lymph node involvement was registered (right inguinal). It has also been documented that thrombocytopenia, anemia and, to a lesser extent, neutropenia can appear as hematologic disorders [4]. On the contrary, this patient’s initial laboratory values were within normal parameters.

Treatment of BPDCN in pediatric patients is still controversial. Even if some intents have been made to create a treatment regimen [16], a gold standard is still far away. Most cases report good response with the same regimen used for ALL, recording remission rates of 93%, compared to 77% of the regimen for chronic myeloid leukemia and 80% of the treatment for lymphoma [3,6,16]. The most favorable results are usually seen in patients without skin involvement [4]. AL-like regimen includes prophylaxis of the nervous system with intrathecal chemotherapy, since it is considered one of the main causes of morbidity and mortality in patients with this disease [12]. Bone marrow transplantation is usually reserved for cases with one or multiple relapses; in elderly patients it is also used as a consolidation therapy after chemotherapy, and it has shown to reduced disease relapses, especially allo-genic hematopoietic stem cell transplant [8,11,15,17]. However, in pediatric patients it does not improve survival [3]. In this patient, institutional HR-ALL was given with good results, adding to the literature its efficacy in a different sociodemographic setting [18].

Various studies identify skin involvement as the initial manifestation (76% of adults and 79% of children) and also the most frequent [3].
These lesions are often asymptomatic and purplish or erythematous in appearance; however, they can also be pseudo-purple, plaque, nodular, equinomorphic, scaly or ulcerated [12]. The most compromised regions are usually the face, scapular region and to a lesser extent the trunk and extremities [4]. In this pediatric case of BPDCN, skin involvement was exclusively appendicular, it compromised soft tissue (solid tumor) and had a loko-regional presentation in the lower right limb (inner side of the right leg with a purplish tone). In adults, a disseminated form with or without skin involvement has been associated with a poorer overall and progression free survival rates [8].

4. Conclusion

To our knowledge, this is the first case report of BPDCN in a Hispanic child outside the US, which adds information about its course in this ethnic group. BPDCN is a diagnostic and therapeutic challenge in pediatrics, especially in the presence of nodular skin lesions from slow and progressive growth that does not seem to cause discomfort.

The decision of the oncology pediatric team was based on literature and similar unpublished cases from the institution. Emphasis should be placed on timely diagnostic through the use of immunohistochemical markers. The treatment of BPDCN with an institutional high-risk ALL regimen has reached very good results in this pediatric case, achieving a 37 month overall and progression-free survival to date.

5. Author contributions

All authors contributed and critically revised the manuscript. The authors would like to thank Melvi Guerrero Quiroga MC from the Pathology department of INEN for her assistance with Histopathology of pediatrics, especially in the presence of nodular skin lesions from slow and progressive growth that does not seem to cause discomfort.

Informed consent was signed by the patient’s proxy.

6. Ethics statement

The author(s) received no financial support for the research, authorship, and/or publication of this article.



K.O. Tanchiva et al.  
Leukemia Research Reports 16 (2021) 100262  

Software, Supervision. Neharka Bhardwaj: Validation, Visualization. Frederick Lansigan: Writing – review & editing. Erik Deconinck: Writing – review & editing.

Declaration of Competing Interest

The authors declare no conflict of interest.

References

[1] D.A. Arber, A. Orazi, R. Hasserjian, et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood 127 (20) (2016) 2391–2405.
[2] G.S. Guru Murthy, N. Pemmaraju, E. Atallah, Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm, Leuk. Res. 73 (2018) 21–23.
[3] M.J. Kim, A. Naor, B. Kabir, et al., Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review, J. Pediatr Hematol. Oncol. 39 (7) (2017) 528–537.
[4] H.S. Kim, H.J. Kim, S.H. Kim, et al., Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea, Korean J. Intern. Med. 32 (5) (2017) 890–899.
[5] Q.T. Kong, M. Zhang, H. Sang, et al., Blastic plasmacytoid dendritic cell neoplasm of the skin associated with myelodysplastic syndrome, Dermatol. Online J. 21 (3) (2014).
[6] L. Pagano, C.G. Valentini, S. Grammatico, A. Pulsoni, Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutic approaches, Br J. Haematol. 174 (2) (2016) 188–202.
[7] J.D. Khoury, Blastic plasmacytoid dendritic cell neoplasm, Curr. Hematol. Malig. Rep. 13 (6) (2018) 477–483.
[8] K. Lakshmi, A. Bouquier de Matteure, M. Sobh, et al., Blastic plasmacytoid dendritic cell neoplasm: results of an international survey on 398 adult patients, Blood Adv. 4 (19) (2020) 4838–4848.
[9] F. Garnache-Ottou, C. Villañ, S. Biichtet, et al., How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood (2019).
[10] N. Pemmaraju, A.A. Lane, K.L. Sweet, et al., Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm, N. Engl. J. Med. 380 (17) (2019) 1628–1637.
[11] 2nd D. Kerr, L. Sokol, The advances in therapy of blastic plasmacytoid dendritic cell neoplasm, Expert Opin. Investig. Drugs 27 (9) (2018) 733–739.
[12] K. Sweet, Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment, Curr. Opin. Hematol. 27 (2) (2020) 103–107.
[13] X. Zhang, J. Sun, M. Yang, L. Wang, J. Jin, New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm, Crit. Rev. Oncol. Hematol. 149 (2020), 102928.
[14] A.M. Trottier, S. Cerquozzi, C.J. Owen, Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects, Blood Lymphat. Cancer 7 (2017) 85–93.
[15] K. Sakashita, S. Saito, R. Yanagisawa, et al., Usefulness of allogeneic hematopoietic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: a case report and review of literature, Pediatr. Blood Cancer 60 (11) (2013) E140-E142.
[16] J.M. Sullivan, D.A. Rizzieri, Treatment of blastic plasmacytoid dendritic cell neoplasm, Hematology Am. Soc. Hematol. Educ. Program. 2016 (1) (2016) 16–23.
[17] M.A. Kharfan-Dabaja, M.M. Al Malki, U. Deotare, et al., Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study, Br. J. Haematol. 179 (5) (2017) 781–789.
[18] A.G. Jegalian, N.P. Buxbaum, F. Facchetti, et al., Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications, Haematologica 95 (11) (2010) 1873–1879.